Amgen

3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
3 Big Drugmakers Most Likely to Make Acquisitions After Pfizer's Surprise Deal
Motley Fool
Pfizer
Array Biopharma
M&A
Amgen
Gilead Sciences
Biogen
Flag link:
Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads
Amgen, Lilly, Merck sue HHS to block price disclosures in DTC ads
BioCentury
HHS
DTC ads
television ads
Merck
Eli Lilly
Amgen
Flag link:
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
RAPS.org
FDA
biosimilars
Roche
Herceptin
Amgen
Kanjinti
Flag link:
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Will The Introduction Of A Third Potent Cholesterol Lowering Drug Expand or Shrink The Market?
Forbes
The Medicines Company
Amgen
Sanofi
Regeneron
inclisiran
PCSK9 inhibitors
Flag link:
3 takeaways from cancer's biggest conference
3 takeaways from cancer's biggest conference
Biopharma Dive
Amgen
KRAS
accelerated approvals
Turning Point Therapeutics
Keytruda
Opdivo
ASCO 2019
Flag link:
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More
Xconomy
ASCO 2019
cancer
immunotherapy
diagnostics
Veracyte
Grail
Moderna Therapeutics
Amgen
Nektar Therapeutics
Blueprint Medicines
Merck
AstraZeneca
Roche
breast cancer
Flag link:
Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients
Amgen Cancer Treatment Candidate Had 'Adverse Events' in Almost Half of Patients
TheStreet.com
Amgen
AMG 420
Multiple Myeloma
Flag link:
3 Cancer Stocks Given a Lift by Amgen
3 Cancer Stocks Given a Lift by Amgen
Motley Fool
Amgen
KRAS
AMG 510
Mirati Therapeutics
Array Biopharma
Gilead Sciences
ASCO 2019
Flag link:
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Did This Biotech Giant Just Find The Key To An 'Undruggable' Protein?
Investors Business Daily
Amgen
AMG 510
KRAS
ASCO 2019
lung cancer
colon cancer
Flag link:
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Early cancer drug data give Amgen hope it's 'cracked KRAS code'
Biopharma Dive
ASCO 2019
KRAS
lung cancer
colorectal cancer
pancreatic cancer
Amgen
AMG 510
Flag link:
3 Charts Every Amgen Investor Needs to See
3 Charts Every Amgen Investor Needs to See
Motley Fool
Amgen
Flag link:
Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm
Mass exodus of Amgen sales reps sparks legal battle with multiple myeloma rival Karyopharm
Fierce Pharma
Amgen
sales poaching
drug reps
Karyopharm Therapeutics
Multiple Myeloma
Selinexor
Flag link:
Amgen offers $167m for drug discovery biotech Nuevolution
Amgen offers $167m for drug discovery biotech Nuevolution
Pharmaforum
Amgen
Nuevolution
R&D
M&A
Flag link:
Here's Why Mirati Therapeutics Is Surging Today
Here's Why Mirati Therapeutics Is Surging Today
Motley Fool
Mirati Therapeutics
Amgen
KRAS inhibitors
MRTX849
AMG 510
Flag link:
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
May 15 ASCO Quick Takes: After-hours pop for Iovance, MacroGenics; plus Takeda, Amgen, Forty Seven
BioCentury
Iovance
LN-145
cervical cancer
Takeda
TAK-788
non-small cell lung cancer
Amgen
AMG-510
Macrogenics
margetuximab
HER2-positive metastatic breast cancer
Forty Seven
Flag link:
How can Teva's migraine drug face off Amgen and Lilly? Put neurologists first, DTC last, executive says
How can Teva's migraine drug face off Amgen and Lilly? Put neurologists first, DTC last, executive says
Fierce Pharma
Teva Pharmaceutical
migraines
Ajovy
Amgen
Eli Lilly
Emgality
Aimovig
neurologists
physicians
DTC advertising
Flag link:
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs
Yahoo/Benzinga
biotech
Achillion
Sesen Bio
The Medicines Company
Amgen
Daiichi Sankyo
earnings
Flag link:
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions
Yahoo/Reuters
Eli Lilly
Amgen
Teva Pharmaceutical
migraines
Emgality
Aimovig
Flag link:
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
Xconomy
migraines
CGRP blockers
Aimovig
Amgen
Ajovy
Teva Pharmaceutical
Emgality
Eli Lilly
Flag link:
Amgen, Syapse enter precision medicine collaboration in oncology
Amgen, Syapse enter precision medicine collaboration in oncology
Pharmaceutical Business Review
Amgen
Syapse
precision medicine
oncology
cancer
Flag link:

Pages